Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2026-05-26 16:54:16 ET · period of report 2026-05-21 · accession 0001470831-26-000488 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-05-26 16:54 | 2026-05-21 | BBIO | Kumar Neil | CEO, Dir | S - Sale | $69.44 | -26.1K | 243.3K | -10% | -$1.81M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-21 | S | D | 2,256 | $67.57 | 267,174 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. (F2) Represents the weighted average sale price of the shares sold from $66.81 to $67.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2026-05-21 | S | D | 6,725 | $68.30 | 260,449 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. (F3) Represents the weighted average sale price of the shares sold from $67.81 to $68.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-05-21 | S | D | 5,072 | $69.22 | 255,377 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. (F4) Represents the weighted average sale price of the shares sold from $68.81 to $69.78 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2026-05-21 | S | D | 11,250 | $70.48 | 244,127 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. (F5) Represents the weighted average sale price of the shares sold from $69.86 to $70.85 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| 5 | Common | Common Stock | 2026-05-21 | S | D | 800 | $70.92 | 243,327 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. (F6) Represents the weighted average sale price of the shares sold from $70.86 to $70.97 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |